Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570635 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
A Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT00570635: Completed Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors, sponsored by Exelixis.
NCT00570635 is a Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors that has completed, run by Exelixis. The registered enrollment target is 16 participants, below the 965-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570635, a Phase 2 study of Gastrointestinal Neoplasms and Gastrointestinal Stromal Tumors, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
Conditions Studied
Interventions
- DRUG XL820
Study Locations (3)
California
- - Los Angeles
Illinois
- - Park Ridge
Massachusetts
- - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00570635 record still lists
NCT00570635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 965-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which XL820 is the first listed.
NCT00570635 reports a single indexed study location in California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00570635 about?
NCT00570635 is a clinical study titled "A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib". The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or intolerant of Imatinib and/or Sunitinib.
What is the current status of trial NCT00570635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-12. Estimated completion is 2009-05.
What conditions does trial NCT00570635 study?
This clinical trial studies the following conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT00570635?
The interventions under investigation include: XL820 (DRUG).
Who is sponsoring clinical trial NCT00570635?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00570635 being conducted?
This trial has 3 study locations across California, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00570635's enrollment target sits among peer trials
16 13th of 12 the lowest of 12 other Gastrointestinal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avatrombopag vs. Placebo for CIT in GI Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RECRUITING · Phase 3
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia